GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group A/S (OCSE:PEG) » Definitions » Forward PE Ratio

Pharma Equity Group A/S (OCSE:PEG) Forward PE Ratio : 0.00 (As of Jun. 12, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Pharma Equity Group A/S Forward PE Ratio?

Pharma Equity Group A/S's Forward PE Ratio for today is 0.00.

Pharma Equity Group A/S's PE Ratio without NRI for today is 0.00.

Pharma Equity Group A/S's PE Ratio for today is 0.00.


Pharma Equity Group A/S Forward PE Ratio Historical Data

The historical data trend for Pharma Equity Group A/S's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group A/S Forward PE Ratio Chart

Pharma Equity Group A/S Annual Data
Trend
Forward PE Ratio

Pharma Equity Group A/S Quarterly Data
Forward PE Ratio

Competitive Comparison of Pharma Equity Group A/S's Forward PE Ratio

For the Biotechnology subindustry, Pharma Equity Group A/S's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Equity Group A/S's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group A/S's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group A/S's Forward PE Ratio falls into.



Pharma Equity Group A/S Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Pharma Equity Group A/S  (OCSE:PEG) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Pharma Equity Group A/S Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group A/S's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Equity Group A/S (OCSE:PEG) Business Description

Traded in Other Exchanges
N/A
Address
Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970
Pharma Equity Group A/S is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develops technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement.